Program Overview
Understanding the Basics of Tumor Lysis Syndrome
Release date: September 30, 2008 Expiration Date: September 29, 2010
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The activity provides 1.0 hour (0.1 CEU) of continuing pharmacy education credit (program number 204-000-08-442-H01P).
Methods and Format
This is an online activity consisting of audio, presentation slides, post-test, and activity evaluation tool. Participants must view the entire presentation, take the activity post-test, and complete the course evaluation to receive continuing pharmacy education credit. A minimum score of 70% is required on the test for credit to be awarded, and participants may print their official statements of continuing pharmacy education credit immediately. The estimated time to complete this activity is one hour. This activity is provided free of charge
Target Audience
This continuing pharmacy education program was planned to meet the needs of pharmacists who practice in oncology or are interested in improving the identification and management of tumor lysis syndrome (TLS).
Activity Content
This web-based basics CE program, Understanding the Basics of Tumor Lysis Syndrome, serves as introduction to the oncologic emergency, tumor lysis syndrome (TLS), for participants planning to attend a Level 2 live symposium, webinar, or those who plan to participate in the web-based, Beyond the Basics symposium. It also serves as a basic introduction to TLS for those with an interest in the topic.
This web-based basics CE program will lay the groundwork for the Level 2 symposium content and will include information about assessing a patient’s risk for developing TLS, recognizing the clinical manifestations and laboratory values suggestive of TLS, and summarizing current treatment options
Learning Objectives
After participating in this knowledge-based educational activity, participants should be able to
- Assess a patient’s risk for developing tumor lysis syndrome (TLS), based on tumor type and associated predictive factors.
- Describe the clinical manifestations and laboratory values suggestive of TLS in at-risk patients.
- Summarize current treatment options for the prophylaxis and management of tumor lysis syndrome.
Presentation Faculty
Susannah E. Koontz, Pharm.D., BCOP
Clinical Pharmacy Specialist
Pediatric Hematology/Oncology/SCTCT
Children's Cancer Hospital at The University of Texas M.D. Anderson Cancer Center
Houston, Texas
Educational Initiative Program Chairs
Susannah E. Koontz, Pharm.D., BCOP
Clinical Pharmacy Specialist
Pediatric Hematology/Oncology/SCTCT
Children's Cancer Hospital at The University of Texas M.D. Anderson Cancer Center
Houston, Texas
Kamakshi V. Rao, Pharm.D., BCOP
Oncology Clinical Pharmacy Specialist
University of North Carolina Hospitals and Clinics
Chapel Hill, North Carolina
Disclosure Statements
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Guidelines for Standards for Commercial Support, ASHP Advantage requires that all individuals involved in the development of program content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the CME activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on presentations.
All faculty and planners for ASHP Advantage education activities are qualified and selected by ASHP Advantage and required to disclose any relevant financial relationships with commercial interests. ASHP Advantage identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity.
The faculty and planners report the following relationships:
Susannah E. Koontz, Pharm.D., BCOP declares that she has served as a speaker for Genzyme Oncology and Enzon Pharmaceuticals.
Kamakshi V. Rao, Pharm.D., BCOP declares that she has no relationships pertinent to this activity.
Erika L. Thomas, M.B.A, R.Ph. declares that she has no relationships pertinent to this activity
This activity is supported by an educational grant from sanofi-aventis.
Launch Presentation
Understanding the Basics of Tumor Lysis Syndrome
Susannah E. Koontz, Pharm.D., BCOP
Download Post-Test
Click here to print the post-test for your reference. Please note that to be eligible for continuing pharmacy education credit, you must go to the ASHP Learning Center and complete the test online.
